Acrivon Therapeutics financials
$2.05−1.44%
Close Sep 30, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — |
| Operating income | -$84.1M | -$89.2M | -$67.1M | -$32.7M |
| Net income | -$77.9M | -$80.6M | -$60.4M | -$31.2M |
| Net margin | — | — | — | — |
| Diluted EPS | $-2.02 | $-2.38 | $-2.74 | $-7.56 |
| EBITDA | -$82.8M | -$88.2M | -$66.6M | -$32.3M |
| Operating cash flow | -$63.7M | -$65.7M | -$42.6M | -$30.1M |
| Free cash flow | -$65.3M | -$68.4M | -$43.9M | -$32.3M |
| Diluted shares | 38.5M | 33.8M | 22.1M | 4.1M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|
| Cash & equivalents | $41.5M | $39.8M | $36.0M | $29.5M |
| Short-term investments | $77.1M | $139.7M | $91.4M | $98.2M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $129.7M | $196.6M | $138.3M | $181.2M |
| Total liabilities | $17.2M | $19.8M | $17.1M | $10.8M |
| Shareholders' equity | $112.5M | $176.8M | $121.2M | $170.5M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology